good speak are everyone. new Ziopharm. Thanks, with Chris to welcome and have of to to who you afternoon you We're we the opportunity pleased those today. And
oral to solid in solid plan treat build By way tumors. our XXXX alone be Ziopharm of patients introduction, believe stands to the able upon in dramatic we offer forward We treatments took tumors. to vision steps to the with
upon that clinical technologies advanced based multiple We have and been innovative data. widely preclinical have convincing published
and our to X each of have on partners. with X INDs them Phase clinical and have class world alignment We execute across programs,
by solid tenure. to-date is treasury, addressing strongest after we With possible in million $XXX our now largest position under going tumors. my Ziopharm approximately in oncology markets its Finally, are the fundamental
size our highlight we the on We've been this to will execute accelerate and could gives since ability focus and successfully accomplished It sheet independence the us and Our few. on great forced scale our corporate to period, I tumors. towards time a months a deal during balance has XX solid truly vision. needed just
In addition all for property have intellectual contracts have of the cooperation multiple programs, critical we Anderson TCR-T, developments trials Street licensed in with having outreach. our to R&Ds we expanded and Wall secured our MD business extending into in have and we
assets. a much of spent understanding third each with of to gain proposition of for also our parties We core XXXX well-known deeper long-term valuation working the
and to our that We to develop T-cell anticipated are accelerating beyond. we are using for manufacturer feedback, our blueprint need information products. ability competitive XXXX Based and on analysis,
requirement upcoming commercial to or to starts plans finishes control trials it’d manufacturing. commercial offer be This whether clinical with to true viability term is for path and our longer our therapy. Our a
Since infrastructure for T-cell accelerating produce XXXX, are been we've investing these products to in ourselves, in Texas. efforts talent Houston, and and
from spaces have two additional and next MD Anderson open months. Center facilities Cancer leased in laboratory we’ll We the
include were and on multiple had We January, manufacturing details and meetings will more plans in GMP we have the JP ATR this expanding At work buy-side, with share to pharma. we which this TCR-T, up scaling already our execute year. begun for sell-side Morgan for manufacturing, about large
we going we to oncology have T-cell It are for advantage unique is collectively the five is theme that dominant competitive tumors areas readily believe solid of apparent us. after and XXXX,
T-cell cells. and we're to cancer attack First, infusing kill
tumor. eliminate As kilograms the proven a of ability reminder, to administration has of a T-cell
target we're which TCRs and their Second, in are types tumors multiple present using new of are heel. antigens, to solid Achilles'
to beauty which harness system of the have solid sleeping Fourth, manufacturing non-viral the from recycle multitudes scale patients engaging use different to we immune cytokines control address needed fifth, And to from staying on to the T-cells of types modifying response. achieve tumors. function we the and genetically so eliminate plasmids based the are we killing blood, power Third, peripheral tumor. with DNA
are upside year. executing data, plan as our with throughout base. in public we a we strong as gain financial the clinical right the on have Especially, right and potential with We assets right and company now place tremendous a the
President, Laying will out QX turning Shukla, the recent programs; the this the agenda call for prepared as conclude our as then discuss operator remarks call to CFO, questions. with our XXXX the timelines returns; updated of and our for financings, Sath then well for core David our Mauney, each over the before financial will
IND an therefore, and the our We and update trial recognize TCR-T how With on patients information the X this to update me Steve based to we of remain come first the with recent where we why remains provide the by most guidance several on trial let status game-changing and wanted Rosenberg NCI about is more that Ziopharm. Phase provide program. study. relative Dr. That's granular to dosing on delays the first in The on feedback start relieve past with for this our this concern on that, study an trials stand starting. the at excited I’ll NCI
we several puts team. enrolled. includes research the for group production an any place In This recent process. great NCI learned have the that of is trial deal there months, for After first NCI NCI steps and the is before are transfer IND to a cleared, in about patient the manufacturing
identified been diligently our patient near Drew Rosenberg Dr. and sleeping his manufacturing had produce Denninger working enrollment, have we process and used TCR-T. with As to to Dr. the team, group improvements and modified
are I'm helped Their exactly report TCR-T happy our to also of upon the be are a Anderson. that the in interim, at MD to Anderson. as the neo-antigens most to is will that have the program appropriate patients on first This then will Rosenberg system. clinical the as data the which considered at year. enroll patients NCI, they TCRs when NCI the which build our to only and undertaken sleeping beauty these made. process TCR towards through come I These the proven first first have continue final the input resected what the to going moves Dr. reviewed ready engineering this and estimate candidates the they tumors The very identified production the NCI patient. significantly be for new completed study. want our Based engine who learnings their we procurement benefit is of In but also control own moving recent to of the half of partner program runs, ingenuity. with the Ziopharm this do efforts the not T-cells, of use de-risk evaluated from NCI, treat as study in will trial the we
we're We with and eager are to plans enrollment, first to for process share the enrolled. NCI of news updates the and patient confident the
I've mentioned our January’s under program control. webcast in we the bring are update, TCR-T implementing also plans to
important new One research which XXth growing program, MD our on announcement for home encompass team an of October our development milestones year's and and provides TCR-T with agreement last of was interest Houston. and our the expanded Anderson to in
MD target with TCR’s Ziopharm on differentiator it's two relationship execute existing solid infusing it neo-antigens One us for approaches enables library in to uses as The competitive to led a significant in tumors. TCR-T occurring Anderson hotspots. a
produce work packs at the methodology IMD the chance system and many treat tumors. NCI is TCR-T target the on These Both two neo-antigens. provide the use developed types based beauty the personalized patients under of to using approaches NCI. to the of other to us sleeping The best solid same
to Indeed, targeting of At program. patient MD Anderson, set hotspots. patients access our in we flow library neo-antigens TCR-T TCRs the enrollment solid TCRs begin variety hotspot licensed can to with anticipate we of the will of to accelerate expansion a NCIs and trial. our and already tissues significant enroll to enough the patients tumors is and the The of
We roadmap, and FDA continue currently regulatory on targeting tumors. our to in work approaches engaged on are with neo-antigens solid two our
open an with believe provides for We the and these head IND with NCI a that us Phase template II having a start discussions. already
will protocols we the strong patients have success tremendous progress. we've the a value TCR-T opportunity tremendous of is a everything seen discussions We to-date, chance as updates provide those program and The believe for we creation. timing With company. in and regarding
we positive orphan program, controlled Next, will designation have program. us fast we track made on clinical IL-XX in I received granting Europe, drug In IL-XX designation. received an XXXX, feedback our in considerable touch FDA and and our progress
have XX patients highest We with XX patients to combination completed the study in included studies, levels. dosing enrollment our at glioblastoma or expansion the two X Phase GBM with which monotherapy patients an and dose treated the study escalation additional XX Opdivo, recurrent in
come online enrollments last GBM sites five third the X Regeneron's for now study should in of XXXX, Libtayo, seven call, study that half recurrent of recurrent in in combination sites a than over received dose with XXXX. Phase at effect. desired quarter achieved alone. additional GBM anti-tumor clinical the have first quarterly Beginning In an have our been those commenced and with veledimex, XX since we with complete XX steriods, Since with of quarters enrolled patients. XX immune-mediated of help than XXXX enrolling three we patients patients which more total, milligram IL-XX low treated believe the More dosing patients XX of
patients immune The indications, encouraging inform on results outside can we IL-XX potentially the in GBM. GBM, patient recurrent or meaningfully it our will of expected later then clinical program the decision from if and help believe stage combination many and these in in with data studies extend recurrent alone improve checkpoint to-date inhibitors. additional have either other outcomes in could cancer that We this effective seen be
or presented monotherapy journal can during XXXX, were and found at main Neuro-Oncology Web of August. ASCO published Results Phase in to in SNO, also these the the our Medicine published Translational were X presentations on site. from or from Science Links Society in November. data June these studies at be Considerable the last including trial
presentation months regression ago provided glioblastoma first Our of of on a imaging. evidence for team's the time at SNO based few
We recurrent median demonstrating survival receiving presented dose overall patients in data, disease low month steroids. unifotal XX also confirmatory with
increasing SNO Ziopharm that note on are interest at based JP five also encouraged in the community the investment at data, to and pleased among potential Morgan. our are with partners we the team top and this meetings these consistent award by received the is This enthusiasm program. We
to continue the with in abstracts the medical first enrolled anticipate major in monitor providing meetings patients half additional for this updates and studies We at year. potential of of submission these multiple the
announced cleared at in XXXX we FDA Anderson. trial that program. I MD will our to investigator October clinical the conducted another with Phase for had X conclude update an initiated be important an IND CAR-T on milestone, In
criteria. leukemias process, donor soon the As as we release personalized marrow lymphomas we can evaluate the Under study transplantation. expressing will after the derived in RPM stated, CAR-T this through but rapid with CDXX verification at who bone day and as CAR-T transfer, including RPM allogeneic after patients created patients previously or infusion relapsed have those have manufacturing gene needs
call, working quarterly last we of Anderson to started trial get said our was the our with During the team by MD end hard XXXX.
the the investigator As to site underway principal our half year, look Indeed a sharing rounded regulatory patient trial, our in product MD initiation of we the the the pleased And qualification coming with were the as well of to forward first by transition first initiation visit or the is we planned I'm this step you you the Anderson are for some gone in study things And important the near-term and weeks. batches their referred for Final is to an delays facility. manufacturing for milestone this GMP tell have year. to SIV experienced this views being is technology as company. But reminder, identified study. since. required as out with
CDXX of and autologous with infusion. years infused malignancies, XX% outcomes all marrow patients demonstrated data regarding sleeping two use Four overall after term bone the XX% reprogram was generation progression are in Blood recent of system T-cells. of on encoring month of free infusion refractory received whom specific mention had encouraging sustained technology. persistence transplantation. the this a respectively. sleeping of to B-cell beauty items or describe Five-year relapsed journal after our This long lymphoid and beauty many published survival modified outcome of based CAR-T CAR-T CAR-T patients we There survival to long-term additional Last prior
the Last data the reduce new the show from annual validating membrane data anti-tumor preclinical effects. and rapid system complexity meeting exhibited on express our T-cell team manufacturing therapies. sleeping bound ASH with December, TCR. These T-cells plasmids personalized to to our These presented beauty cost modified that genetically build IL-XX approach of with using XXXX TCR results at DNA
Things technology BioCell. and have in They on hospital we are our the uptake RPM scientists well runs is venture currently Taiwanese the the conducting an The progress Greater Finally, large first and our to of staffed Eden as China. with joint the at tech is commenced for complete, a trial GMP discussions Taipei. in continue transfer the also to FDA largely facility manufacturing colleagues start process. the equipped test with expect RPM
BioCell the situation corona CDXX advise Taiwan. to-date this the Eden's we virus It not partners Eden to significant filed with new for work IND is Our while will are us prevented year. be that will trial ability noting at worth to experiencing in restrictions continue And monitored, not RPM the be delays. have China autologous the in CAR-T travel
In data the past And breadth Ziopharm. of to programs, Shukla. RPM and now, for will progress T. potential funds These TCR-T, have controlled the our throughout significant hand we CFO, creating future; programs technology, unique call and have summary, this significant the over dispose opportunities we I for appears value provide expect CAR months, the well assembled the insight to and XX our to upside and Sath in deeper year clinical made all on people and into IL-XX
